EndoCure has developed Revealan™, a robotic ultrasound imaging system that achieves 1mm lesion detection with 100X higher resolution than MRI, enabling precise mapping and staging of endometriosis lesions. This technology addresses the significant diagnostic delay and inaccuracy in identifying superficial pathologies, which often leads to severe health complications for affected women.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for endometriosis, such as standard ultrasound, often fail to detect superficial lesions smaller than 5mm, leading to diagnostic delays and inaccurate staging of the disease. These limitations can result in prolonged suffering and severe health complications for women with endometriosis.
Solution
EndoCure's Revealan™ is a robotic ultrasound imaging system designed to improve the detection and mapping of endometriosis lesions. The system utilizes a robotic arm to perform 3D ultrasound imaging, achieving 100X higher resolution than MRI. This enables the detection of lesions as small as 1mm, providing a more objective and detailed assessment of the condition, independent of operator skill. The enhanced resolution and precision of Revealan™ aim to facilitate earlier and more accurate diagnosis, leading to improved treatment planning and patient outcomes.
Target Audience
The primary target audience includes healthcare providers, such as gynecologists and radiologists, specializing in women's health, as well as hospitals and diagnostic centers focused on improving endometriosis diagnosis and treatment.
Features
- Robotic-arm ultrasound system for operator-independent scanning
- High-resolution imaging capable of detecting 1mm lesions
- 3D ultrasound imaging for precise mapping and staging of endometriosis
- 100X higher resolution compared to MRI